Prilenia

Prilenia is a clinical-stage biotechnology company dedicated to improving the lives of patients and their families by developing treatments for neurodegenerative diseases and neurodevelopmental disorders. The company is led by Michael Hayden and an experienced team. Its lead product, pridopidine, is a highly selective sigma-1 receptor (S1R) agonist with a well-established safety profile and potential in a variety of movement disorders and neurodegenerative diseases affecting both adults and children.